LifeSpan BioSciences brings in Everest Biotech

SEATTLE—LifeSpan BioSciences, Inc. (LSBio), a provider of antibodies and life science research reagents, is pleased to announce its acquisition of Everest Biotech Ltd. Everest Biotech is a ISO 9001:2015 certified expert in antigen affinity purified goat polyclonal antibodies.

“We are looking forward to adding the Everest Biotech product range to the LSBio portfolio,” said Heather Holemon, CEO of LifeSpan BioSciences. “Everest Biotech products are of exceptionally high quality and perfectly complement our existing portfolio.”

The acquisition of Everest Biotech further expands LSBio’s product offering and strengthens the company’s position as one of the fastest growing providers in the research reagent market. Through its partnerships, LSBio now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies.

The Everest Biotech catalogue contains thousands of goat antibodies against a broad range of human, mouse and rat targets of biomedical interest. The acquisition of Everest Biotech will broaden the LSBio offering of over 500,000 monoclonal and polyclonal primary antibodies to include virtually every protein in the proteome. Through extensive ongoing in-house testing, more than 15,000 of the LSBio antibodies have also been identified as exceptional IHC reagents and given the IHC-plus brand.

This deal with Everest Biotech marks the second investment by LSBio this year, following the company’s successful acquisition of Nordic MUbio BV in February. Nordic MUbio is a ISO 9001:2015 certified expert in developing antibodies targeting cell adhesion, nuclear and cytoskeletal proteins.

“We are very happy to be adding the Nordic MUbio product ranges, which also includes Exalpha Biologicals Inc., Gallus Immunotech & Biologo, to the LSBio portfolio,” noted Holemon in a press release. “Nordic MUbio’s products are of exceptionally high quality and they complement our existing portfolio perfectly.”

LSBio itself was acquired by Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, back in September of 2018. The terms of the transaction were not disclosed.

“We’re excited to be partnering with the founders of LSBio. The company fills a highly specific niche in its industry and enjoys a well-deserved reputation for excellence, innovation and customer service,” Bob Dunn, a managing director and head of Acquisitions at TSCP, mentioned at the time. “LSBio’s ongoing mission is to expand upon its capabilities to provide the vital materials necessary for fueling important scientific research. We’re proud to help facilitate the ongoing growth of LifeSpan Biosciences.”